NCT00094705View on ClinicalTrials.gov

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Dengue Fever
Interventions
BIOLOGICAL

rDEN2/4delta30(ME) Vaccine

Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)

BIOLOGICAL

Placebo

Placebo for rDEN2/4delta30(ME) vaccine

Trial Locations (1)

21205

Johns Hopkins School of Public Health, Baltimore

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00094705 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults | Biotech Hunter | Biotech Hunter